A hydrogel-based drug delivery device refers to a biomedical technology that uses hydrogels as matrices or carriers for controlled and targeted release of therapeutic agents. Hydrogels are three-dimensional networks of cross-linked hydrophilic polymers capable of absorbing and retaining large amounts of water. These devices are designed to encapsulate drugs or biomolecules, providing a stable environment for sustained or localized release in response to physiological stimuli such as pH, temperature, or enzymatic activity. Hydrogel-based drug delivery systems offer advantages like enhanced bioavailability, reduced systemic side effects, and prolonged therapeutic efficacy. They are utilized in various medical applications including wound healing, tissue engineering, cancer therapy, and treatment of chronic diseases, demonstrating versatility and potential for personalized medicine approaches.
The global Hydrogel-based Drug Delivery Device market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Hydrogel-based Drug Delivery Device is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Hydrogel-based Drug Delivery Device is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Hydrogel-based Drug Delivery Device include AstraZeneca Plc., Columbia Laboratories Inc., Mylan, Teva Pharmaceuticals USA Inc., Blairex Laboratories Inc., ARx LLC., Endo International plc, BioDelivery Sciences International Inc., Indivior PLC, GSK Plc, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hydrogel-based Drug Delivery Device, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hydrogel-based Drug Delivery Device.
The Hydrogel-based Drug Delivery Device market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Hydrogel-based Drug Delivery Device market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hydrogel-based Drug Delivery Device manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
AstraZeneca Plc.
Columbia Laboratories Inc.
Mylan
Teva Pharmaceuticals USA Inc.
Blairex Laboratories Inc.
ARx LLC.
Endo International plc
BioDelivery Sciences International Inc.
Indivior PLC
GSK Plc
Pfizer Inc.
Aquestive Therapeutics Inc.
ZIM LABORATORIES LIMITED
IntelGenx Corp.
NEXGEL
Bliss GVS Pharma Ltd.
Teika Pharmaceutical Co. Ltd.
Medherant Limited
Galderma
Johnson & Johnson
Bausch and Lomb
Ferring B.V
Segment by Type
Oral
Buccal
Rectal
Vaginal
Other
Segment by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hydrogel-based Drug Delivery Device manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hydrogel-based Drug Delivery Device in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Hydrogel-based Drug Delivery Device 麻豆原创 Overview
1.1 Product Definition
1.2 Hydrogel-based Drug Delivery Device by Type
1.2.1 Global Hydrogel-based Drug Delivery Device 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Oral
1.2.3 Buccal
1.2.4 Rectal
1.2.5 Vaginal
1.2.6 Other
1.3 Hydrogel-based Drug Delivery Device by Application
1.3.1 Global Hydrogel-based Drug Delivery Device 麻豆原创 Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Hydrogel-based Drug Delivery Device 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Hydrogel-based Drug Delivery Device Revenue 2019-2030
1.4.2 Global Hydrogel-based Drug Delivery Device Sales 2019-2030
1.4.3 Global Hydrogel-based Drug Delivery Device 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Hydrogel-based Drug Delivery Device 麻豆原创 Competition by Manufacturers
2.1 Global Hydrogel-based Drug Delivery Device Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Hydrogel-based Drug Delivery Device Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Hydrogel-based Drug Delivery Device Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Hydrogel-based Drug Delivery Device, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hydrogel-based Drug Delivery Device, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hydrogel-based Drug Delivery Device, Product Type & Application
2.7 Global Key Manufacturers of Hydrogel-based Drug Delivery Device, Date of Enter into This Industry
2.8 Global Hydrogel-based Drug Delivery Device 麻豆原创 Competitive Situation and Trends
2.8.1 Global Hydrogel-based Drug Delivery Device 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Hydrogel-based Drug Delivery Device Players 麻豆原创 Share by Revenue
2.8.3 Global Hydrogel-based Drug Delivery Device 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Hydrogel-based Drug Delivery Device 麻豆原创 Scenario by Region
3.1 Global Hydrogel-based Drug Delivery Device 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Hydrogel-based Drug Delivery Device Sales by Region: 2019-2030
3.2.1 Global Hydrogel-based Drug Delivery Device Sales by Region: 2019-2024
3.2.2 Global Hydrogel-based Drug Delivery Device Sales by Region: 2025-2030
3.3 Global Hydrogel-based Drug Delivery Device Revenue by Region: 2019-2030
3.3.1 Global Hydrogel-based Drug Delivery Device Revenue by Region: 2019-2024
3.3.2 Global Hydrogel-based Drug Delivery Device Revenue by Region: 2025-2030
3.4 North America Hydrogel-based Drug Delivery Device 麻豆原创 Facts & Figures by Country
3.4.1 North America Hydrogel-based Drug Delivery Device 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Hydrogel-based Drug Delivery Device Sales by Country (2019-2030)
3.4.3 North America Hydrogel-based Drug Delivery Device Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Hydrogel-based Drug Delivery Device 麻豆原创 Facts & Figures by Country
3.5.1 Europe Hydrogel-based Drug Delivery Device 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Hydrogel-based Drug Delivery Device Sales by Country (2019-2030)
3.5.3 Europe Hydrogel-based Drug Delivery Device Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hydrogel-based Drug Delivery Device 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Hydrogel-based Drug Delivery Device 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Hydrogel-based Drug Delivery Device Sales by Region (2019-2030)
3.6.3 Asia Pacific Hydrogel-based Drug Delivery Device Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Hydrogel-based Drug Delivery Device 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Hydrogel-based Drug Delivery Device 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Hydrogel-based Drug Delivery Device Sales by Country (2019-2030)
3.7.3 Latin America Hydrogel-based Drug Delivery Device Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Hydrogel-based Drug Delivery Device 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Hydrogel-based Drug Delivery Device 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Hydrogel-based Drug Delivery Device Sales by Country (2019-2030)
3.8.3 Middle East and Africa Hydrogel-based Drug Delivery Device Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Hydrogel-based Drug Delivery Device Sales by Type (2019-2030)
4.1.1 Global Hydrogel-based Drug Delivery Device Sales by Type (2019-2024)
4.1.2 Global Hydrogel-based Drug Delivery Device Sales by Type (2025-2030)
4.1.3 Global Hydrogel-based Drug Delivery Device Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Hydrogel-based Drug Delivery Device Revenue by Type (2019-2030)
4.2.1 Global Hydrogel-based Drug Delivery Device Revenue by Type (2019-2024)
4.2.2 Global Hydrogel-based Drug Delivery Device Revenue by Type (2025-2030)
4.2.3 Global Hydrogel-based Drug Delivery Device Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Hydrogel-based Drug Delivery Device Price by Type (2019-2030)
5 Segment by Application
5.1 Global Hydrogel-based Drug Delivery Device Sales by Application (2019-2030)
5.1.1 Global Hydrogel-based Drug Delivery Device Sales by Application (2019-2024)
5.1.2 Global Hydrogel-based Drug Delivery Device Sales by Application (2025-2030)
5.1.3 Global Hydrogel-based Drug Delivery Device Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Hydrogel-based Drug Delivery Device Revenue by Application (2019-2030)
5.2.1 Global Hydrogel-based Drug Delivery Device Revenue by Application (2019-2024)
5.2.2 Global Hydrogel-based Drug Delivery Device Revenue by Application (2025-2030)
5.2.3 Global Hydrogel-based Drug Delivery Device Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Hydrogel-based Drug Delivery Device Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AstraZeneca Plc.
6.1.1 AstraZeneca Plc. Company Information
6.1.2 AstraZeneca Plc. Description and Business Overview
6.1.3 AstraZeneca Plc. Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AstraZeneca Plc. Hydrogel-based Drug Delivery Device Product Portfolio
6.1.5 AstraZeneca Plc. Recent Developments/Updates
6.2 Columbia Laboratories Inc.
6.2.1 Columbia Laboratories Inc. Company Information
6.2.2 Columbia Laboratories Inc. Description and Business Overview
6.2.3 Columbia Laboratories Inc. Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Columbia Laboratories Inc. Hydrogel-based Drug Delivery Device Product Portfolio
6.2.5 Columbia Laboratories Inc. Recent Developments/Updates
6.3 Mylan
6.3.1 Mylan Company Information
6.3.2 Mylan Description and Business Overview
6.3.3 Mylan Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mylan Hydrogel-based Drug Delivery Device Product Portfolio
6.3.5 Mylan Recent Developments/Updates
6.4 Teva Pharmaceuticals USA Inc.
6.4.1 Teva Pharmaceuticals USA Inc. Company Information
6.4.2 Teva Pharmaceuticals USA Inc. Description and Business Overview
6.4.3 Teva Pharmaceuticals USA Inc. Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Teva Pharmaceuticals USA Inc. Hydrogel-based Drug Delivery Device Product Portfolio
6.4.5 Teva Pharmaceuticals USA Inc. Recent Developments/Updates
6.5 Blairex Laboratories Inc.
6.5.1 Blairex Laboratories Inc. Company Information
6.5.2 Blairex Laboratories Inc. Description and Business Overview
6.5.3 Blairex Laboratories Inc. Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Blairex Laboratories Inc. Hydrogel-based Drug Delivery Device Product Portfolio
6.5.5 Blairex Laboratories Inc. Recent Developments/Updates
6.6 ARx LLC.
6.6.1 ARx LLC. Company Information
6.6.2 ARx LLC. Description and Business Overview
6.6.3 ARx LLC. Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.6.4 ARx LLC. Hydrogel-based Drug Delivery Device Product Portfolio
6.6.5 ARx LLC. Recent Developments/Updates
6.7 Endo International plc
6.7.1 Endo International plc Company Information
6.7.2 Endo International plc Description and Business Overview
6.7.3 Endo International plc Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Endo International plc Hydrogel-based Drug Delivery Device Product Portfolio
6.7.5 Endo International plc Recent Developments/Updates
6.8 BioDelivery Sciences International Inc.
6.8.1 BioDelivery Sciences International Inc. Company Information
6.8.2 BioDelivery Sciences International Inc. Description and Business Overview
6.8.3 BioDelivery Sciences International Inc. Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.8.4 BioDelivery Sciences International Inc. Hydrogel-based Drug Delivery Device Product Portfolio
6.8.5 BioDelivery Sciences International Inc. Recent Developments/Updates
6.9 Indivior PLC
6.9.1 Indivior PLC Company Information
6.9.2 Indivior PLC Description and Business Overview
6.9.3 Indivior PLC Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Indivior PLC Hydrogel-based Drug Delivery Device Product Portfolio
6.9.5 Indivior PLC Recent Developments/Updates
6.10 GSK Plc
6.10.1 GSK Plc Company Information
6.10.2 GSK Plc Description and Business Overview
6.10.3 GSK Plc Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.10.4 GSK Plc Hydrogel-based Drug Delivery Device Product Portfolio
6.10.5 GSK Plc Recent Developments/Updates
6.11 Pfizer Inc.
6.11.1 Pfizer Inc. Company Information
6.11.2 Pfizer Inc. Description and Business Overview
6.11.3 Pfizer Inc. Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Pfizer Inc. Hydrogel-based Drug Delivery Device Product Portfolio
6.11.5 Pfizer Inc. Recent Developments/Updates
6.12 Aquestive Therapeutics Inc.
6.12.1 Aquestive Therapeutics Inc. Company Information
6.12.2 Aquestive Therapeutics Inc. Description and Business Overview
6.12.3 Aquestive Therapeutics Inc. Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Aquestive Therapeutics Inc. Hydrogel-based Drug Delivery Device Product Portfolio
6.12.5 Aquestive Therapeutics Inc. Recent Developments/Updates
6.13 ZIM LABORATORIES LIMITED
6.13.1 ZIM LABORATORIES LIMITED Company Information
6.13.2 ZIM LABORATORIES LIMITED Description and Business Overview
6.13.3 ZIM LABORATORIES LIMITED Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.13.4 ZIM LABORATORIES LIMITED Hydrogel-based Drug Delivery Device Product Portfolio
6.13.5 ZIM LABORATORIES LIMITED Recent Developments/Updates
6.14 IntelGenx Corp.
6.14.1 IntelGenx Corp. Company Information
6.14.2 IntelGenx Corp. Description and Business Overview
6.14.3 IntelGenx Corp. Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.14.4 IntelGenx Corp. Hydrogel-based Drug Delivery Device Product Portfolio
6.14.5 IntelGenx Corp. Recent Developments/Updates
6.15 NEXGEL
6.15.1 NEXGEL Company Information
6.15.2 NEXGEL Description and Business Overview
6.15.3 NEXGEL Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.15.4 NEXGEL Hydrogel-based Drug Delivery Device Product Portfolio
6.15.5 NEXGEL Recent Developments/Updates
6.16 Bliss GVS Pharma Ltd.
6.16.1 Bliss GVS Pharma Ltd. Company Information
6.16.2 Bliss GVS Pharma Ltd. Description and Business Overview
6.16.3 Bliss GVS Pharma Ltd. Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Bliss GVS Pharma Ltd. Hydrogel-based Drug Delivery Device Product Portfolio
6.16.5 Bliss GVS Pharma Ltd. Recent Developments/Updates
6.17 Teika Pharmaceutical Co. Ltd.
6.17.1 Teika Pharmaceutical Co. Ltd. Company Information
6.17.2 Teika Pharmaceutical Co. Ltd. Description and Business Overview
6.17.3 Teika Pharmaceutical Co. Ltd. Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Teika Pharmaceutical Co. Ltd. Hydrogel-based Drug Delivery Device Product Portfolio
6.17.5 Teika Pharmaceutical Co. Ltd. Recent Developments/Updates
6.18 Medherant Limited
6.18.1 Medherant Limited Company Information
6.18.2 Medherant Limited Description and Business Overview
6.18.3 Medherant Limited Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Medherant Limited Hydrogel-based Drug Delivery Device Product Portfolio
6.18.5 Medherant Limited Recent Developments/Updates
6.19 Galderma
6.19.1 Galderma Company Information
6.19.2 Galderma Description and Business Overview
6.19.3 Galderma Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Galderma Hydrogel-based Drug Delivery Device Product Portfolio
6.19.5 Galderma Recent Developments/Updates
6.20 Johnson & Johnson
6.20.1 Johnson & Johnson Company Information
6.20.2 Johnson & Johnson Description and Business Overview
6.20.3 Johnson & Johnson Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Johnson & Johnson Hydrogel-based Drug Delivery Device Product Portfolio
6.20.5 Johnson & Johnson Recent Developments/Updates
6.21 Bausch and Lomb
6.21.1 Bausch and Lomb Company Information
6.21.2 Bausch and Lomb Description and Business Overview
6.21.3 Bausch and Lomb Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Bausch and Lomb Hydrogel-based Drug Delivery Device Product Portfolio
6.21.5 Bausch and Lomb Recent Developments/Updates
6.22 Ferring B.V
6.22.1 Ferring B.V Company Information
6.22.2 Ferring B.V Description and Business Overview
6.22.3 Ferring B.V Hydrogel-based Drug Delivery Device Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Ferring B.V Hydrogel-based Drug Delivery Device Product Portfolio
6.22.5 Ferring B.V Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hydrogel-based Drug Delivery Device Industry Chain Analysis
7.2 Hydrogel-based Drug Delivery Device Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hydrogel-based Drug Delivery Device Production Mode & Process
7.4 Hydrogel-based Drug Delivery Device Sales and 麻豆原创ing
7.4.1 Hydrogel-based Drug Delivery Device Sales Channels
7.4.2 Hydrogel-based Drug Delivery Device Distributors
7.5 Hydrogel-based Drug Delivery Device Customers
8 Hydrogel-based Drug Delivery Device 麻豆原创 Dynamics
8.1 Hydrogel-based Drug Delivery Device Industry Trends
8.2 Hydrogel-based Drug Delivery Device 麻豆原创 Drivers
8.3 Hydrogel-based Drug Delivery Device 麻豆原创 Challenges
8.4 Hydrogel-based Drug Delivery Device 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
AstraZeneca Plc.
Columbia Laboratories Inc.
Mylan
Teva Pharmaceuticals USA Inc.
Blairex Laboratories Inc.
ARx LLC.
Endo International plc
BioDelivery Sciences International Inc.
Indivior PLC
GSK Plc
Pfizer Inc.
Aquestive Therapeutics Inc.
ZIM LABORATORIES LIMITED
IntelGenx Corp.
NEXGEL
Bliss GVS Pharma Ltd.
Teika Pharmaceutical Co. Ltd.
Medherant Limited
Galderma
Johnson & Johnson
Bausch and Lomb
Ferring B.V
听
听
*If Applicable.
